Y Intercept Hong Kong Ltd Purchases Shares of 69,236 Ventyx Biosciences, Inc. $VTYX

Y Intercept Hong Kong Ltd acquired a new position in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) in the second quarter, HoldingsChannel.com reports. The institutional investor acquired 69,236 shares of the company’s stock, valued at approximately $148,000.

A number of other large investors have also recently made changes to their positions in the company. Pallas Capital Advisors LLC purchased a new position in Ventyx Biosciences in the second quarter worth approximately $38,000. Cerity Partners LLC purchased a new stake in shares of Ventyx Biosciences in the 1st quarter valued at approximately $56,000. Jane Street Group LLC purchased a new stake in shares of Ventyx Biosciences in the 1st quarter valued at approximately $56,000. CWM LLC raised its holdings in shares of Ventyx Biosciences by 1,733.8% in the 1st quarter. CWM LLC now owns 53,088 shares of the company’s stock valued at $61,000 after purchasing an additional 50,193 shares in the last quarter. Finally, Cutter & CO Brokerage Inc. purchased a new stake in shares of Ventyx Biosciences during the 1st quarter worth $62,000. 97.88% of the stock is currently owned by hedge funds and other institutional investors.

Ventyx Biosciences Price Performance

Shares of NASDAQ:VTYX opened at $8.77 on Monday. The stock has a market cap of $625.39 million, a P/E ratio of -5.85 and a beta of 1.21. The firm has a fifty day moving average price of $4.21 and a 200 day moving average price of $2.93. Ventyx Biosciences, Inc. has a 1-year low of $0.78 and a 1-year high of $9.50.

Ventyx Biosciences (NASDAQ:VTYX) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.13. Sell-side analysts expect that Ventyx Biosciences, Inc. will post -2.09 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on VTYX. Wall Street Zen upgraded shares of Ventyx Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, August 9th. Wells Fargo & Company lifted their price target on Ventyx Biosciences from $11.00 to $14.00 and gave the stock an “overweight” rating in a report on Friday. Canaccord Genuity Group increased their price objective on Ventyx Biosciences from $14.00 to $16.00 and gave the company a “buy” rating in a report on Friday. HC Wainwright raised Ventyx Biosciences from a “neutral” rating to a “buy” rating and set a $18.00 target price on the stock in a research report on Wednesday. Finally, Oppenheimer upped their price target on Ventyx Biosciences from $9.00 to $14.00 and gave the company an “outperform” rating in a report on Monday, October 27th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $15.50.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.